Understand what you own.

India's second-largest glass-bottle maker, whose operating margin doubled mainly because its largest rival collapsed into bankruptcy and left the market. That rival is now being revived by a well-funded new owner just as AGI takes on debt to expand, so the whole case reduces to one number: how much of today's fat margin survives the competitor's return?

An effectively debt-free building contractor whose profit compounded while the stock fell a third, so the market is now valuing a proven builder at about 19 times earnings. The catch is that its quarters are lumpy, and it just printed a bad one.

India's number-two truck maker, well run and at its strongest in years, but priced at 28 times earnings near the top of a cycle that always turns.

India's best lender has one real edge: it picks borrowers who pay back. You pay 5.9 times book for that spotless record, and the record just showed its first crack.

The lost decade is over: three players left, tariffs rising, cash finally pouring in. The only problem now is the price, 46 times earnings for a turn nobody can miss.

A genuinely good business (visa outsourcing is a two-horse global race with fat margins and clean cash) fell 36%, and now trades at 15 times earnings. The core is still excellent. The worry is that the edges are getting muddier.

CDSL is a toll booth on India's stock market, a regulated duopoly earning 40% on capital as demat accounts pile up. But two of its three toll lanes only fill when trading and IPOs are busy, so profit fell 13.5% in a quiet FY26, and you still pay 61 times earnings.

CAMS keeps the books for two-thirds of India's mutual-fund money and earns 47% on capital. But the more money it minds, the smaller its cut of each rupee, so revenue crawls while the assets race.

In FY26, Dilip Buildcon reported ₹1,398 crore of profit. Of that, ₹65 crore came from actually building roads. The other ₹1,396 crore came from selling them.

India's biggest contract electronics factory, where brands bring the design and Dixon does the assembly. Profit compounded 35% a year for a decade on pure volume, and the stock actually got cheaper recently because earnings outran the share price. At 3.8% operating margins, you are betting the orders never stop.

eClerx does the specialised back-office grind big banks would rather not touch, and it does it brilliantly: growing 22%, earning 35% on capital. Yet the stock has de-rated, because it gets paid by the head, and AI is coming for exactly that kind of work.

Emmvee makes its own solar cells in a country that is short of them, which is why it earns a fat made-in-India premium and a 34% margin that the market values cheaply at about 17 times earnings. The catch is that the premium looks like a policy-and-shortage window rather than a permanent edge, and everyone in the industry is racing to build the cells that will close it.

The quiet supplier of the foam in your shampoo and the mildness in your face wash, sold to the world's FMCG giants. The ingredients are sticky and the balance sheet is spotless, yet sales grew by half over five years while profit went nowhere, which tells you who really holds the pricing power.

A near-monopoly on how Indian men shave, with a 91% return on capital and margins that keep climbing, but growth is slow, a slice of profit leaks to its parent P&G, and you pay 37 times earnings to own a business you effectively rent.

It sells the grinding wheels and sandpaper that Indian factories wear out and buy again, which is about as steady a business as manufacturing offers. Profit has grown 3% a year over three years and you are being asked 49 times earnings for it.

The pitch was 'born digital, no legacy,' and it once fetched 80 times earnings. Every IT firm does digital now, profit has not grown in three years, and at 24 times flat earnings the story premium has shrunk but not vanished.

A scarce, approved vendor of Kavach, India's train-collision-avoidance system, whose profit tripled in a year as the railway rollout began. The stock de-rated anyway, because the market cannot yet tell a durable new base from a one-year spike.

A toll booth on India's rising river of savings: it earns a small fee on every rupee it manages, at 62% net margins and 33% return on equity, and hands most of it back as dividends. The catch is that the toll rate keeps getting cut, and the river can run dry in a bad market.

A niche animal vaccine maker that looks cheap at 14 times earnings, until you strip out one quarter's windfall other income and find you are actually paying 35 times for a business growing 9% a year.

Two thirds of the revenue is Novelis, an American business that melts used drink cans back into sheet. It is midway through a build that has taken borrowings up by half and free cash flow deep into the red, which is why 11 times earnings is not the bargain it looks like.

India's only copper miner, and at 46 times earnings the market has already priced the whole electrification story into the ticket.

India's biggest owner of mobile towers, spinning off cash and a near-4% dividend at just 14 times earnings. It looks cheap until you see how much of it leans on one struggling tenant.

India's dominant maker of cryogenic tanks, debt-free and earning a third on capital, riding the LNG wave. You just have to pay 75 times earnings to stand there.

ITC pays you a 5.2% dividend and earns 29% on equity, yet trades like a problem stock. The problem is simple: cigarettes fund almost everything, and the taxman takes a bigger slice every few years.

It makes the steel springs that sit between a truck's axle and its chassis, and it makes about two thirds of the ones fitted to new Indian trucks. That share is the whole business, and it means Jamna cannot grow faster than Indian truck sales for very long.

An Ayurvedic hospital chain that is really a medicine company wearing a hospital's clothes, because roughly half its revenue is product carrying about 85% gross margin sold to patients its own clinics recruited. That is how a healthcare provider comes to earn a 44% operating margin and 61% on equity, and why the entire stock now rests on one number: whether that 44% was a level or a peak.

Kalyan sells trust, and it sells it well. The catch is the price: 46 times earnings, with a quarter of the promoter's stake pledged to lenders.

India's largest mid-price hotel chain, earning record profits at 48% margins, and the stock fell 40% in a year. At 29 times peak-cycle earnings, you are paying for the upcycle to last while the market is pricing it to end.

Lupin went from losing money to a 29% margin in four years, a genuine turnaround. The catch: a good chunk of that margin is US exclusivity money, and exclusivities expire.

A rare Indian carmaker leading two races at once, number one in SUVs and number one in tractors, and doing it at a price that does not yet demand perfection.

Muthoot's loans are backed by gold locked in its vault, so they almost never go bad. It earns 31% on equity and still trades at 10 times earnings, because everyone knows those returns ride the price of gold.

One of the few companies in the world that can handle fluorine safely at scale, finally converting a decade of climbing up the value chain into a breakout year. The chemistry is a real moat. The price already assumes the breakout is a floor, not a peak.

Sales have grown at roughly 5% a year over a decade while net profit went from a ₹4 crore loss to ₹97 crore, because every rupee of that came from margin rather than from selling more. The margin is made of crushed animal bone and Kerala river water, and the neighbours have been trying to shut the plant since 2013.

India's only electric bus maker at scale, growing profit 26% a year on a wave of government orders. At 55 times earnings, the stock prices in a decade of those orders arriving on time. Government orders in India do not arrive on time.

India's second-largest private phosphatic-fertiliser maker, whose revenue nearly tripled in four years while it sold barely more fertiliser. Almost all the 'growth' is commodity prices and government subsidy passing through a thin, state-set spread that does not reliably turn into cash, so the real question is not how fast it is growing but how little of that growth it actually keeps.

PC Jeweller nearly went under and is now being repriced as a turnaround, but the profit that makes it look healthy is flattered by the mechanics of escaping its debt (a collapsed interest bill, one-time settlement gains, a near-zero tax rate), the cash flow is still negative, and the promoter had to flood the market with new shares to survive.

PFC is a government-owned lender that funds India's power grid. It earns 21% on equity, yields over 5%, and trades below its book value, because the market cannot decide whether it is a cheap compounder or a state utility that will be told what to do.

Screener files it under iron and steel, and in the June 2026 quarter power earned 4.4 times what steel did. What you are actually buying is a Chhattisgarh power company that still makes steel on the side, midway through spending ₹2,657 crore on a coal plant it won out of bankruptcy court.

Its real asset is not a factory but a stack of hard-won permits to sell generic crop chemicals across dozens of countries, and at 11 times earnings it is cheap, debt-free and cash-rich. The catch is that those chemicals are commodities, and their prices just put it through a year when profit fell ninety percent.

A solar plant builder that a mechanical screen flags as cheap and growing, but the low P/E is an illusion (it is loss-making), the original promoter sold down heavily, and institutions are leaving. A turnaround, not a bargain.

Suzlon came back from near-bankruptcy to become India's biggest wind maker, and it is now net cash. The question is no longer survival but price, and whether the recovery can scale without its margins and its cash slipping.

Tata Consumer sells tea and salt to half of India and is spending billions to add sauces, health food and coffee, but at 59 times earnings and a 7% return on equity, you are paying full price for a portfolio that has not yet earned its keep.

India's lowest-cost diagnostics 'factory', a capital-light cash machine (about 35% returns on capital, almost no debt, most of its profit paid out as dividends) priced at 51 times earnings, a multiple that leaves little room for slower growth or moat erosion, even as its earnings have only just clawed back to their COVID-era peak, a distressed owner sells down the register, and venture-funded rivals attack the one thing it is built on: being cheap.

Time Technoplast makes the plastic drums and tanks that ship the world's chemicals and fuels. The steady part pays the bills. The bet is composite gas cylinders, and at 19 times earnings the market is not handing you that bet for free.

It owns a catalogue of songs already written and paid for, and the streaming boom now rents them out at 73% operating margins and a 118% return on capital. The question is what you pay for a business that good, and why the promoter keeps selling.

UltraTech is the king of Indian cement, gushing cash and buying up rivals. But you are paying 41 times earnings for a commodity business that earns just 11% on its equity, and those two numbers do not belong on the same stock.

Revenue nearly doubled and profit rose 65%, and yet the company went to its own promoters to raise ₹16 crore for working capital. The accounts explain why: this builder is running on other people's money at both ends, and the bill has not come due yet.

It makes about 65% of the world's supply of two obscure molecules, one that goes into ibuprofen and one that helps pull oil out of the ground. Owning most of a small market turns out to be a ceiling as well as a moat, and the share price has spent five years discovering that.

It builds solar power plants for other people and earns an astonishing 84% on capital doing it, cheaply too, at 18 times earnings after the stock lagged a twentyfold jump in profit. The catch is that this is the same solar-EPC business that once cost Sterling and Wilson thousands of crore.